Figure 2. Ectopic expression of PRPS1 or PRPS2 has no effects on cell metabolism and drug resistance in PSCs. (A, B) qRT-PCR analysis of PRPS1 (A) and PRPS2 (B) mRNA levels in various PSCs and somatic cells. CB iPS, induced pluripotency stem cell derived from cord blood; PB iPS A or B, induced pluripotency stem cell derived from peripheral blood of two different healthy human. (C) WB of endogenous expression of PRPS1 and PRPS2 in PSCs and somatic cells from (A, B). (D, E) qRT-PCR analysis of overexpression of PRPS1 wild type (WT), WT PRPS2, or PRPS1 A190T mutant in PSCs (CB iPS cells). (F) WB of overexpression of PRPS1, PRPS2 or PRPS1 A190T mutant in PSCs from (D). (G) Heatmap showing the metabolomics in the PSCs from (D). (H) Effect of 6-MP or 6-TG treatment on PSCs viability. ***P< 0.001. In (D, E and H), data are expressed as the mean ± SD. *P <0.05, ***P <0.001, by two-tailed t-test. Data are representative of three independent experiments with similar results.